Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan

Heidelberg University9 enrolled

Overview

Due to the withdrawal of Thelin (Sitaxentan) in December 2010 all patients with pulmonary hypertension treated with Sitaxentan need to be switched to an alternative therapy. This study will observe in which way the change of medication - in the clinical routine, without exception in charge of the treating physician - affects clinical and laboratory parameters and patient's quality of life.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hypertension, Pulmonary

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pulmonary hypertension * Treatment with Sitaxentan Exclusion Criteria: * Inability or unwillingness to give written informed consent

Locations (1)

Department of Clinical Pharmacology and Pharmacoepidemiology, Medical department of the University of Heidelberg

Heidelberg, Baden-Wurttemberg, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.